Singapore (PRWEB) January 10, 2014
Moleac, a privately held specialty biopharmaceutical company specializing in neurological disorders, announced that CEO David Picard will present at the 2014 Biotech Showcase in San Francisco on January 15 at 1:45 p.m. PST.
Moleac focuses on therapeutic areas including neurology and aging and leverages the natural components of medicine to pursue listing with health authorities, while implementing stringent control following Good Manufacturing Practice (GMP) standards for the medicine’s production.
Moleac will provide an overview of its neurorestorative drug, NeuroAiD™ during its Biotech Showcase presentation. NeuroAid is the first medicine that brings a faster, more full recovery to stroke patients and is registered and marketed in over 25 countries. David Picard will be available for one-on-one meetings with investors and media attending the conference as the company readies itself for the build out of additional indications for NeuroAiD™.
Event Biotech Showcase 2014
Date January 15, 2014
Time 1:45 PM PST
Place C-Mission II, 3rd Floor
Parc 55 Wyndham San Francisco, Union Square
To address therapeutic gaps, Moleac has pioneered a new drug development approach, looking at sources of innovation from traditional medicines, hence shortening considerably drug development cycle time and investment to bring medicine to sufferers’ unaddressed needs. Moleac’s neurorestorative medicine NeuroAiD™ reaches patients in more than 25 countries.
617-374-8800 ext 107
For Investors and Potential Partners:
Assistant Account Executive
617-374-8800 ext 101